Improved detection of cystic fibrosis by the California Newborn Screening Program for all races and ethnicities

Abstract

BackgroundNewborn screening (NBS) for cystic fibrosis (CF) is universal in the United States. Protocols vary but include an immunoreactive trypsinogen (IRT) level and CFTR variant panel. California CF NBS has a 3‐step screening: IRT level, variant panel, and CFTR sequencing if only one variant identified on panel.MethodsThis was a cohort study of infants with CF born in California (2007−2021) to examine racial and ethnic differences in having a false‐negative NBS result for CF and at which step the false‐negative occurred. We examined how different CFTR variant panels would improve detection of variants by race and ethnicity: original 39‐variant panel, current 75‐variant panel, and all 402 disease‐causing CFTR variants in the CFTR2 database.ResultsOf the 912 infants born in California with CF, 84 had a false‐negative result: 38 due to low IRT level and 46 with a high IRT value (but incomplete variant detection). Asian (OR 6.3) and Black infants (OR 2.5) were more likely to have a false‐negative screening result than non‐Hispanic white infants. The majority of false‐negative screening (but CF diagnosis) cases among American Indian/Native Alaskan and non‐Hispanic White infants were due to low IRT levels. The majority of Asian and Hispanic infants with false‐negative screening had no variants detected. Detection of two CFTR variants was improved with the 75‐variant panel in Black, Hispanic, and non‐Hispanic White infants and with the 402‐variant panel in Black, Hispanic, non‐Hispanic White, and other race infants.ConclusionsLarger CFTR panels in NBS improved the detection of CF in all races and ethnicities.